Talmadge E King Jr

List of Publications by Year in Descending Order

127 papers	31,104 citations	76 h-index	128 g-index
128 ext. papers	36,589 ext. citations	10.8 avg, IF	6.7 L-index

#	Paper	IF	Citations
127	Cryptogenic Organizing Pneumonia.. *New England Journal of Medicine*, **2022**, 386, 1058-1069	59.2	1
126	The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. *Thorax*, **2017**, 72, 424-429	7.3	81
125	The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. *Respiratory Medicine*, **2017**, 127, 51-56	4.6	33
124	Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model. *Chest*, **2017**, 152, 999-1007	5.3	40
123	Lessons From an Educational Never Event. *JAMA Internal Medicine*, **2017**, 177, 1415-1416	11.5	7
122	Idiopathic Interstitial Pneumonias **2016**, 1118-1152.e19		
121	Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. *European Respiratory Journal*, **2016**, 47, 243-53	13.6	244
120	Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. *BMJ Open Respiratory Research*, **2016**, 3, e000105	5.6	77
119	Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. *Thorax*, **2016**, 71, 429-35	7.3	112
118	A diagnostic model for chronic hypersensitivity pneumonitis. *Thorax*, **2016**, 71, 951-4	7.3	53
117	The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2015**, 109, 1058-62	4.6	7
116	Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2015**, 109, 914-22	4.6	55
115	Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. *Lancet Respiratory Medicine,the*, **2015**, 3, 388-96	35.1	57
114	Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. *Chest*, **2015**, 148, 196-201	5.3	26
113	A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. *European Respiratory Journal*, **2015**, 46, 243-9	13.6	35
112	Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. *Respirology*, **2015**, 20, 389-94	3.6	4
111	American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002. *Radiographics*, **2015**, 35, 1849-71	5.4	69

110	Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria. *Respiratory Medicine*, **2015**, 109, 1326-31	4.6	33
109	CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society. *Lancet Respiratory Medicine,the*, **2015**, 3, 483-96	35.1	95
108	Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. *Respirology*, **2014**, 19, 740-7	3.6	79
107	Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. *New England Journal of Medicine*, **2014**, 370, 2093-101	59.2	343
106	A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *New England Journal of Medicine*, **2014**, 370, 2083-92	59.2	2111
105	All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 825-31	10.2	92
104	Smoking-related idiopathic interstitial pneumonia. *European Respiratory Journal*, **2014**, 44, 594-602	13.6	27
103	Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 214-22	10.2	159
102	Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. *Respirology*, **2014**, 19, 493-500	3.6	95
101	Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. *Radiology*, **2014**, 270, 583-8	20.5	91
100	Predicting survival across chronic interstitial lung disease: the ILD-GAP model. *Chest*, **2014**, 145, 723-728	5.3	253
99	Idiopathic pulmonary fibrosis: CT and risk of death. *Radiology*, **2014**, 273, 570-9	20.5	66
98	6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2014**, 43, 1421-9	13.6	128
97	An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 733-48	10.2	2176
96	Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2013**, 107, 249-55	4.6	64
95	Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. *Chest*, **2013**, 144, 586-592	5.3	117
94	Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 1272	10.2	2
93	Prevalence and prognosis of unclassifiable interstitial lung disease. *European Respiratory Journal*, **2013**, 42, 750-7	13.6	164

92	Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. *Chest*, **2013**, 144, 234-240	5.3	186
91	A multidimensional index and staging system for idiopathic pulmonary fibrosis. *Annals of Internal Medicine*, **2012**, 156, 684-91	8	642
90	Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. *Thorax*, **2012**, 67, 407-11	7.3	117
89	Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 314-24	10.2	287
88	Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 185, 1044-8	10.2	165
87	Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. *New England Journal of Medicine*, **2012**, 366, 1968-77	59.2	992
86	Diffuse Lung Disease: Classification and Evaluation **2012**, 85-100		2
85	An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 788-824	10.2	4665
84	Idiopathic pulmonary fibrosis. *Lancet, The*, **2011**, 378, 1949-61	40	1196
83	Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. *Lancet, The*, **2011**, 377, 1760-9	40	1286
82	Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 184, 1390-4	10.2	313
81	Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 184, 1382-9	10.2	306
80	Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 184, 459-66	10.2	294
79	Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 1231-7	10.2	291
78	Clinical course and prediction of survival in idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 431-40	10.2	998
77	BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 184, 92-9	10.2	333
76	Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2010**, 299, L3-7	5.8	139
75	The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. *Thorax*, **2010**, 65, 173-7	7.3	97

74	Workshop on idiopathic pulmonary fibrosis in older adults. *Chest*, **2010**, 138, 693-703	5.3	37
73	The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. *Respiratory Medicine*, **2010**, 104, 296-304	4.6	167
72	Does chronic microaspiration cause idiopathic pulmonary fibrosis?. *American Journal of Medicine*, **2010**, 123, 304-11	2.4	156
71	Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility. *Journal of Occupational and Environmental Medicine*, **2010**, 52, 647-52	2	8
70	Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. *Lung*, **2010**, 188, 143-9	2.9	42
69	Idiopathic Interstitial Pneumonias **2010**, 1356-1397		3
68	Understanding Nonspecific Interstitial Pneumonia: The Need for a Diagnostic Gold Standard. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 179, 256-256	10.2	1
67	Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. *Lancet, The*, **2009**, 374, 222-8	40	376
66	Surgical lung biopsy in the diagnosis of idiopathic NSIP: do we always need it in the initial approach?. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 179, 1071; author reply 1071-2	10.2	3
65	Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. *Chest*, **2009**, 136, 1397-1405	5.3	237
64	Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. *Chest*, **2009**, 135, 1557-1563	5.3	152
63	BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 177, 75-81	10.2	407
62	Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 177, 1292-3; author reply 1293	10.2	1
61	Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 177, 1338-47	10.2	425
60	Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. *Chest*, **2008**, 133, 226-32	5.3	166
59	Clinical and Radiologic Diagnosis of Interstitial Infiltrates **2008**, 105-140		
58	Bosentan for idiopathic pulmonary fibrosis. *Current Opinion in Investigational Drugs*, **2008**, 9, 1171-9		6
57	Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. *PLoS ONE*, **2007**, 2, e482	3.7	205

56	Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 175, 1054-60	10.2	190
55	Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 176, 691-7	10.2	293
54	Acute exacerbations of idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 176, 636-43	10.2	823
53	Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate. *Thorax*, **2007**, 62, 1008-12	7.3	45
52	Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias. *Thorax*, **2007**, 62, 546-53	7.3	65
51	Respiratory bronchiolitis-interstitial lung disease: long-term outcome. *Chest*, **2007**, 131, 664-671	5.3	85
50	Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. *Respiratory Medicine*, **2007**, 101, 2011-6	4.6	37
49	Anticoagulant therapy and idiopathic pulmonary fibrosis. *Chest*, **2006**, 130, 302-3	5.3	15
48	Current perspectives on the treatment of idiopathic pulmonary fibrosis. *Proceedings of the American Thoracic Society*, **2006**, 3, 330-8		124
47	Classification and natural history of the idiopathic interstitial pneumonias. *Proceedings of the American Thoracic Society*, **2006**, 3, 285-92		276
46	Idiopathic Interstitial Pneumonias **2006**, 188-197		
45	The clinical course of patients with idiopathic pulmonary fibrosis. *Annals of Internal Medicine*, **2005**, 142, 963-7	8	423
44	COPD: a dust-induced disease?. *Chest*, **2005**, 128, 3055-64	5.3	28
43	Idiopathic interstitial pneumonias: CT features. *Radiology*, **2005**, 236, 10-21	20.5	259
42	High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 172, 488-93	10.2	373
41	Clinical advances in the diagnosis and therapy of the interstitial lung diseases. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 172, 268-79	10.2	215
40	Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. *Chest*, **2005**, 127, 171-7	5.3	181
39	A critical assessment of treatment options for idiopathic pulmonary fibrosis. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*, **2005**, 22, 167-74	1.1	14

38	Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 170, 904-10	10.2	450
37	A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. *New England Journal of Medicine*, **2004**, 350, 125-33	59.2	545
36	The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. *American Journal of Medicine*, **2004**, 116, 662-8	2.4	174
35	Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. *Chest*, **2004**, 125, 2169-74	5.3	112
34	Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management. *Transactions of the American Clinical and Climatological Association*, **2004**, 115, 43-76; discussion 76-8	0.9	4
33	Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 168, 538-42	10.2	556
32	Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic. *Seminars in Respiratory and Critical Care Medicine*, **2003**, 24, 567-76	3.9	17
31	Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. *Chest*, **2003**, 124, 1215-23	5.3	247
30	Demystifying idiopathic interstitial pneumonia. *Archives of Internal Medicine*, **2003**, 163, 17-29		70
29	Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 166, 236-46	10.2	140
28	Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 166, 765-73	10.2	101
27	Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation. *Journal of Computer Assisted Tomography*, **2002**, 26, 13-20	2.2	112
26	Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis. *American Journal of Medicine*, **2002**, 112, 490-3	2.4	86
25	Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. *Annals of Internal Medicine*, **2001**, 134, 136-51	8	1257
24	Elevation of soluble interleukin-2 receptor levels in the bronchoalveolar lavage from patients with systemic sclerosis. *Rheumatology International*, **2001**, 21, 122-6	3.6	5
23	Treatment of idiopathic pulmonary fibrosis: the rise and fall of corticosteroids. *American Journal of Medicine*, **2001**, 110, 326-8	2.4	30
22	Acute interstitial pneumonitis. Case series and review of the literature. *Medicine (United States)*, **2000**, 79, 369-78	1.8	89
21	Correlation of structure and function in idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **1995**, 151, 1180-8	10.2	22

20	RESPIRATORY BRONCHIOLITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE. *Clinics in Chest Medicine*, **1993**, 14, 693-698	5.3	76
19	INFILTRATIVE AND INTERSTITIAL LUNG DISEASE IN THE ELDERLY PATIENT. *Clinics in Chest Medicine* , **1993**, 14, 501-521	5.3	11
18	Cryptogenic Organizing Pneumonitis. *Chest*, **1992**, 102, 8-13	5.3	69
17	Idiopathic pulmonary fibrosis. Quantitative assessment of lung pathology. Comparison of a semiquantitative and a morphometric histopathologic scoring system. *The American Review of Respiratory Disease*, **1992**, 146, 1042-7		50
16	Serum and bronchoalveolar lavage of N-terminal type III procollagen peptides in idiopathic pulmonary fibrosis. *The American Review of Respiratory Disease*, **1992**, 146, 701-6		39
15	Diagnostic advances in idiopathic pulmonary fibrosis. *Chest*, **1991**, 100, 238-41	5.3	14
14	Quantitative assessment of lung pathology in idiopathic pulmonary fibrosis. The BAL Cooperative Group Steering Committee. *The American Review of Respiratory Disease*, **1991**, 144, 892-900		104
13	Pathogenesis of pulmonary fibrosis in interstitial lung disease. Alveolar macrophage PDGF(B) gene activation and up-regulation by interferon gamma. *The American Review of Respiratory Disease*, **1991**, 143, 167-73		90
12	Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage content of surfactant protein A. *The American Review of Respiratory Disease*, **1991**, 144, 160-6		99
11	The impact of smoking on mechanical properties of the lungs in idiopathic pulmonary fibrosis and sarcoidosis. *The American Review of Respiratory Disease*, **1991**, 144, 1102-6		52
10	On the differential diagnosis of chronic beryllium disease and sarcoidosis. *The American Review of Respiratory Disease*, **1990**, 142, 739-40		
9	Collagen cross-linking in adult patients with acute and chronic fibrotic lung disease. Molecular markers for fibrotic collagen. *The American Review of Respiratory Disease*, **1990**, 141, 307-13		53
8	Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. *American Journal of Medicine*, **1990**, 88, 396-404	2.4	282
7	An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. *The American Review of Respiratory Disease*, **1989**, 140, 1693-703		390
6	Pathologic and Immunologic Alterations in Early Stages of Beryllium Disease: Re-examination of Disease Definition and Natural History. *The American Review of Respiratory Disease*, **1989**, 140, 1834-1835		
5	Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. *The American Review of Respiratory Disease*, **1989**, 139, 1479-86		168
4	Idiopathic pulmonary fibrosis. Abnormalities in bronchoalveolar lavage fluid phospholipids. *The American Review of Respiratory Disease*, **1988**, 137, 585-91		78
3	Quantification of cells recovered by bronchoalveolar lavage. Comparison of cytocentrifuge preparations with the filter method. *The American Review of Respiratory Disease*, **1988**, 138, 74-80		87

2	Bronchoalveolar lavage fluid neutrophils increase after corticosteroid therapy in smokers with idiopathic pulmonary fibrosis. *The American Review of Respiratory Disease*, **1986**, 133, 104-9	17
1	A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. *The American Review of Respiratory Disease*, **1986**, 133, 97-103	251